Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRAS Mutant Tumor”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)UnknownNCT02535650
What this trial is testing

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Samsung Medical Center 19
Testing effectiveness (Phase 2)Study completedNCT02383927
What this trial is testing

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Who this might be right for
Thyroid CancerSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)HRAS Mutant Tumor+1 more
Kura Oncology, Inc. 63
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Early research (Phase 1)Study completedNCT03415126
What this trial is testing

ASN007 in Patients With Advanced Solid Tumors

Who this might be right for
CancerMalignancyNeoplasia+16 more
Asana BioSciences 49